Literature DB >> 21516198

Controlling the Evolution of Resistance.

Rutao Luo1, Lamont Cannon, Jason Hernandez, Michael J Piovoso, Ryan Zurakowski.   

Abstract

Evolution has long been understood as the driving force for many problems of medical interest. The evolution of drug resistance in HIV and bacterial infections is recognized as one of the most significant emerging problems in medicine. In cancer therapy, the evolution of resistance to chemotherapeutic agents is often the differentiating factor between effective therapy and disease progression or death. Interventions to manage the evolution of resistance have, up to this point, been based on steady-state analysis of mutation and selection models. In this paper, we review the mathematical methods applied to studying evolution of resistance in disease. We present a broad review of several classical applications of mathematical modeling of evolution, and review in depth two recent problems which demonstrate the potential for interventions which exploit the dynamic behavior of resistance evolution models. The first problem addresses the problem of sequential treatment failures in HIV; we present a review of our recent publications addressing this problem. The second problem addresses a novel approach to gene therapy for pancreatic cancer treatment, where selection is used to encourage optimal spread of susceptibility genes through a target tumor, which is then eradicated during a second treatment phase. We review the recent in Vitro laboratory work on this topic, present a new mathematical model to describe the treatment process, and show why model-based approaches will be necessary to successfully implement this novel and promising approach.

Entities:  

Year:  2011        PMID: 21516198      PMCID: PMC3079266          DOI: 10.1016/j.jprocont.2010.11.010

Source DB:  PubMed          Journal:  J Process Control        ISSN: 0959-1524            Impact factor:   3.666


  50 in total

1.  Production of resistant HIV mutants during antiretroviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.

Authors:  Guimin Chang; Shuping Xu; Makiko Watanabe; Himangi R Jayakar; Michael A Whitt; Jeffrey R Gingrich
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

3.  HIV treatment failure: testing for HIV resistance in clinical practice.

Authors:  L Perrin; A Telenti
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  Pre-existence and emergence of drug resistance in HIV-1 infection.

Authors:  S Bonhoeffer; M A Nowak
Journal:  Proc Biol Sci       Date:  1997-05-22       Impact factor: 5.349

5.  A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma.

Authors:  B Sangro; G Mazzolini; M Ruiz; J Ruiz; J Quiroga; I Herrero; C Qian; A Benito; J Larrache; C Olagüe; J Boan; I Peñuelas; B Sádaba; J Prieto
Journal:  Cancer Gene Ther       Date:  2010-08-06       Impact factor: 5.987

6.  Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.

Authors:  Y Fujita; T Nakamura; T Aomori; H Nishiba; H Shinozaki; T Yanagawa; K Takagishi; H Watanabe; Y Okada; K Nakamura; R Horiuchi; K Yamamoto
Journal:  J Chemother       Date:  2010-06       Impact factor: 1.714

7.  Assessing resistance costs of antiretroviral therapies via measures of future drug options.

Authors:  Hongyu Jiang; Steven G Deeks; Daniel R Kuritzkes; Marc Lallemant; David Katzenstein; Mary Albrecht; Victor DeGruttola
Journal:  J Infect Dis       Date:  2003-09-23       Impact factor: 5.226

8.  Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma.

Authors:  Xin Meng; Takafumi Nakamura; Toshihiko Okazaki; Hiroyuki Inoue; Atsushi Takahashi; Shohei Miyamoto; Gaku Sakaguchi; Masatoshi Eto; Seiji Naito; Makoto Takeda; Yusuke Yanagi; Kenzaburo Tani
Journal:  Mol Ther       Date:  2010-01-05       Impact factor: 11.454

9.  Antitumor therapy based on cellular competition.

Authors:  Jordi Martinez-Quintanilla; Manel Cascallo; Cristina Fillat; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

10.  Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.

Authors:  E H Oldfield; Z Ram; K W Culver; R M Blaese; H L DeVroom; W F Anderson
Journal:  Hum Gene Ther       Date:  1993-02       Impact factor: 5.695

View more
  8 in total

1.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

2.  Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Authors:  D M Rommelfanger; C P Offord; J Dev; Z Bajzer; R G Vile; D Dingli
Journal:  Gene Ther       Date:  2011-09-15       Impact factor: 5.250

3.  Robust closed-loop minimal sampling method for HIV therapy switching strategies.

Authors:  E F Cardozo; R Zurakowski
Journal:  IEEE Trans Biomed Eng       Date:  2012-05-25       Impact factor: 4.538

4.  Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching.

Authors:  E Fabian Cardozo; Ryan Zurakowski
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2011

5.  Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection.

Authors:  Ryan Zurakowski; Matthew Churgin; Camilo Perez; Matthew Rodriguez
Journal:  Proc Am Control Conf       Date:  2011

6.  HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.

Authors:  Rutao Luo; Michael J Piovoso; Javier Martinez-Picado; Ryan Zurakowski
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

7.  Nonlinear observer output-feedback MPC treatment scheduling for HIV.

Authors:  Ryan Zurakowski
Journal:  Biomed Eng Online       Date:  2011-05-27       Impact factor: 2.819

8.  Optimal antiviral switching to minimize resistance risk in HIV therapy.

Authors:  Rutao Luo; Michael J Piovoso; Javier Martinez-Picado; Ryan Zurakowski
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.